The initial step of the process is to understand the nature of the illness from every angle and to the microlevel of genetic and molecular interaction. This systematic approach allows to our team of scientists to model, develop and record numbers of viral variations for most promising lead candidate selection.
The lead contenders should be prepared and scaled for elaborate testing to provide significant evidence of effectiveness and safety in preparation for clinical trials.
A clinical trial is a research study that test new ways to treat serious disease like cancer. The process is conducted to determine safety, biomedical or behavioral effects and new indications of a medical product.
Regulation, Review and Monitoring
If a therapeutic candidate has reached a concluding point of safety and efficiency in the clinical trial process, it is submitted to local or international regulatory agencies for reviewing procedure. However, the R&D process does not stop with the registration
We have set strategic goals for virotherapy product differentiation, advancing our scientific process to create medication for oncological illness. We are determined on development of most promising candidates that demonstrate clinically significant effects and potential in economic value.
- active work in progress on POC according to EMA advice.